Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.46 |
| ▸ | HRH2 | P25021 | 7/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | EEF2K | O00418 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13650612 | 1.00 | HRH3 (0.46) | HRH3HRH4HRH2IRAK4EEF2K | |
| SCHEMBL13650568 | 0.81 | HRH3 (0.49) | HRH3HRH4HRH2EEF2K | |
| SCHEMBL13650551 | 0.81 | HRH3 (0.47) | HRH3HRH4HRH2EEF2K | |
| SCHEMBL13650547 | 0.80 | HRH3 (0.48) | HRH3HRH4HRH2EEF2K | |
| SCHEMBL13650597 | 0.80 | HRH3 (0.49) | HRH3HRH4HRH2EEF2K | |
| SCHEMBL13650550 | 0.80 | HRH3 (0.46) | HRH3HRH4HRH2IRAK4EEF2K | |
| SCHEMBL13650549 | 0.79 | HRH4 (0.45) | HRH3HRH4HRH2IRAK4 | |
| SCHEMBL13650665 | 0.78 | HRH3 (0.45) | HRH3HRH4HRH2EEF2K | |
| SCHEMBL13650667 | 0.78 | HRH3 (0.45) | HRH3HRH4HRH2EEF2K | |
| SCHEMBL13650658 | 0.78 | HRH3 (0.52) | HRH3HRH4HRH2EEF2K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436005-B2 | Macrocyclic pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2009123967-A1 | 5,6,7,8-TETRAHYDROQUINAZOLIN-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ASTHMA | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | HRH3 3555/4885HRH4 3370/4885HRH2 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.